The IPO market is set to host a historic event in the coming week, with SpaceX (SPCX) set to list on Friday. Beyond the headline offering, a few other sizable IPOs are scheduled to price. SpaceX plans to raise $75 billion by offering 555.6 million shares at...read more
Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, announced terms for its IPO on Wednesday. The Cambridge, MA-based company plans to raise $450 million by offering 25 million shares at a price range of $17 to $19....read more
Three IPOs and seven SPACs priced this week. Eight IPOs, including SpaceX (SPCX), and five SPACs submitted filings. Advisory firm Lincoln Financial (LCLN) priced at the top of the range to raise $421 million at a $2.2 billion market cap. Lincoln...read more
Parabilis Medicines, a Phase 3-ready biotech developing engineered peptide therapies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Parabilis Medicines is a clinical-stage biotech developing medicines that...read more
US IPO Week Ahead: SpaceX counts down to its historic $75 billion IPO
The IPO market is set to host a historic event in the coming week, with SpaceX (SPCX) set to list on Friday. Beyond the headline offering, a few other sizable IPOs are scheduled to price. SpaceX plans to raise $75 billion by offering 555.6 million shares at...read more
Cancer biotech Parabilis Medicines sets terms for $450 million IPO
Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, announced terms for its IPO on Wednesday. The Cambridge, MA-based company plans to raise $450 million by offering 25 million shares at a price range of $17 to $19....read more
US IPO Weekly Recap: SpaceX files papers for what could be the largest IPO in history
Three IPOs and seven SPACs priced this week. Eight IPOs, including SpaceX (SPCX), and five SPACs submitted filings. Advisory firm Lincoln Financial (LCLN) priced at the top of the range to raise $421 million at a $2.2 billion market cap. Lincoln...read more
Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO
Parabilis Medicines, a Phase 3-ready biotech developing engineered peptide therapies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Parabilis Medicines is a clinical-stage biotech developing medicines that...read more